कंपनी का अवलोकन
DaVita Inc. operates within the healthcare sector, specifically focusing on the medical care facilities industry by providing essential kidney dialysis services to patients suffering from chronic kidney failure across the United States. The enterprise maintains a substantial operational footprint with 78,000 employees, utilizing outpatient dialysis centers to deliver related laboratory services alongside outpatient, hospital inpatient, and home-based hemodialysis treatments. With a market capitalization of $10.07 billion and an annual revenue of $13.64 billion, the company demonstrates significant scale within its niche. These valuation and revenue figures indicate that DaVita holds a dominant position as a major player in the dialysis care market, reflecting its extensive reach and capacity to serve a large patient base.
वित्तीय स्वास्थ्य
The company reported total revenue of $13.64 billion over the trailing twelve months, generating a net income of $721.80 million and an EBITDA of $2.75 billion. The substantial gap between the $13.64 billion in revenue and the $721.80 million in net income reveals a cost structure where operating expenses, including labor and facility costs, absorb approximately 94.5% of gross sales before reaching the bottom line. Free cash flow stands at $1.05 billion, which signifies a strong ability to generate liquidity from operations after capital expenditures, thereby ensuring financial flexibility for operational investments or potential strategic initiatives. Profitability analysis shows a gross margin of 32.3%, an operating margin of 15.2%, and a profit margin of 5.5%, indicating that while the company maintains pricing power over services, high operational costs significantly impact the final bottom-line profitability. On the liability side, the company holds $700.74 million in cash against total debt of $12.87 billion, resulting in a debt-to-equity ratio of 1111.35, which characterizes a highly leveraged balance sheet where debt obligations substantially exceed equity capitalization. Short-term liquidity is supported by a current ratio of 1.29, suggesting the company possesses sufficient current assets to cover its current liabilities, though with a relatively narrow margin of safety. Return on equity is recorded at 64.8% and return on assets at 7.3%, metrics that reveal management's effectiveness in generating returns on shareholder capital despite the heavy debt burden and asset intensity of the dialysis business model.
मूल्यांकन आकलन
Valuation metrics indicate a trailing P/E ratio of 15.84 and a forward P/E of 9.19, implying that the market expects earnings growth to accelerate significantly in the coming year to justify the lower forward multiple. The price-to-book ratio stands at -15.86, a negative figure that indicates the market is pricing the company's equity below its book value, often reflecting the heavy leverage or specific accounting treatments regarding its substantial debt load. Alternative valuation measures include a price-to-sales ratio of 0.74 and an EV/EBITDA of 8.74, suggesting the stock is trading at a discount relative to its sales volume and earnings before interest, taxes, depreciation, and amortization compared to historical averages for the sector. Regarding price volatility, the stock has traded between a 52-week high of $159.42 and a 52-week low of $101.00, with the current share price situated well below the high, reflecting a correction or consolidation phase within the trading range. The beta value of 0.92 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings than the average healthcare stock.
Growth & Income
Revenue growth is recorded at 9.9% year-over-year, while earnings growth is 6.5% year-over-year, indicating that earnings are expanding at a slower pace than revenue, which often points to margin compression or increased cost pressures offsetting top-line gains. The company currently does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This non-dividend status implies that the company retains all of its earnings to reinvest into the business, likely funding network expansion, technology upgrades, or debt reduction rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by capital appreciation potential rather than current income yield, with growth drivers tied to the expanding dialysis patient population and operational efficiency improvements.